QPS Announces New Fellow of Autoradiography

NEWARK, Del.--(Business Wire)--
QPS, a leading full-service GLP/GCP-compliant contract research organization
(CRO) providing testing services to support preclinical and clinical research
and development, is pleased to announce today the appointment of Eric G. Solon,
Ph.D., to the position of Fellow, Autoradiography DMPK.

QPS CEO and Founder, Ben Chien, Ph.D., said, "I am thrilled with Eric`s
appointment to our first scientific track position. Eric is widely regarded as
one of the industry's leading experts in pioneering the use of autoradiography
in drug discovery and development. In fact, one of his recent
microautoradiography photos was featured in Fox News` The Best Science Photo of
the Week. His new assignment will continue to sharpen QPS` focus on the
innovative use of technology, such as microautoradiography and xenograft, to
identify new opportunities that help our clients accelerate their drug discovery
and development programs."

Dr. Solon has been serving as the Director of Autoradiography for QPS since
2002. Prior to joining QPS, Dr. Solon served as one of the DMPK representatives
of the anti-viral project team at DuPont Pharmaceuticals. He coordinated
preclinical ADME activities for ERC and IND filings and implemented both macro-
and microautoradiography techniques. Before joining DuPont, he held various
scientific posts in toxicology/pathology and DMPK at Ciba-Geigy Pharmaceuticals,
Novartis and Schering-Plough Research Institute. Dr. Solon received his Ph.D. in
molecular biology/pathology from Rutgers University. He is currently the
president ex officio and a course instructor for the Society for Whole-Body
Autoradiography and an ad hoc consultant for AAALAC International.

"QPS` reputation as a quality CRO has been growing consistently since its
inception. The addition of a scientific track to support the discovery and
development of both small molecules and biologic drugs shows a true focus on
science and service," said Dr. Solon. "QPS has been heavily involved in the
development of monoclonal antibodies and oligonucleotide-based drugs. This new
assignment is another commitment to the ongoing DMPK expansion in the biologics
arena. I look forward to continue working with my colleagues on autoradiography,
as well as playing a role in developing new opportunities to help our clients."

About QPS

QPS provides GLP/GCP-compliant preclinical and clinical research services to
pharmaceutical and biotechnology clients worldwide in the areas of bioanalysis,
DMPK, translational medicine research and early-phase clinical research. Our
regional laboratories are located at Newark, Delaware; Springfield, Missouri;
and Taipei, Taiwan. To learn more about QPS, visit www.qps-usa.com.

QPS
Zamas Lam, 302-369-5117 (VP of Non-Clinical Development)
zamas.lam@qps-usa.com

Copyright Business Wire 2010